Stock Track | Zimmer Biomet Plunges 5% Pre-Market as 2025 Outlook Disappoints Despite Q4 Beat

Stock Track

Feb 06, 2025

Zimmer Biomet Holdings Inc. (ZBH) shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.

For Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee implants as well as sports medicine and trauma care products.

However, the company's full-year 2025 adjusted profit guidance of $8.15 to $8.35 per share fell short of Wall Street's consensus estimate of $8.56. Zimmer Biomet expects a 1.5% to 2% negative impact on revenue due to a stronger U.S. dollar. Additionally, its recent acquisition of orthopedic surgical device maker Paragon 28 is expected to weigh on earnings by around 10 cents per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1199395653"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199395653\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199395653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199395653","market":"us","top_or_hot":-1,"title":"Stock Track | Zimmer Biomet Plunges 5% Pre-Market as 2025 Outlook Disappoints Despite Q4 Beat","media":"Stock Track","content":"<p>Zimmer Biomet Holdings Inc. (ZBH) shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.</p>\n\n<p>For Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee implants as well as sports medicine and trauma care products.</p>\n\n<p>However, the company's full-year 2025 adjusted profit guidance of $8.15 to $8.35 per share fell short of Wall Street's consensus estimate of $8.56. Zimmer Biomet expects a 1.5% to 2% negative impact on revenue due to a stronger U.S. dollar. Additionally, its recent acquisition of orthopedic surgical device maker Paragon 28 is expected to weigh on earnings by around 10 cents per share.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zimmer Biomet Plunges 5% Pre-Market as 2025 Outlook Disappoints Despite Q4 Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zimmer Biomet Plunges 5% Pre-Market as 2025 Outlook Disappoints Despite Q4 Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-06 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zimmer Biomet Holdings Inc. (ZBH) shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.</p>\n\n<p>For Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee implants as well as sports medicine and trauma care products.</p>\n\n<p>However, the company's full-year 2025 adjusted profit guidance of $8.15 to $8.35 per share fell short of Wall Street's consensus estimate of $8.56. Zimmer Biomet expects a 1.5% to 2% negative impact on revenue due to a stronger U.S. dollar. Additionally, its recent acquisition of orthopedic surgical device maker Paragon 28 is expected to weigh on earnings by around 10 cents per share.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBH","symbol_name":"齐默巴奥米特控股","start_time":0,"source_url":"","article_id":"1199395653","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199395653","pubTimestamp":1738851027,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zimmer Biomet Holdings Inc.  shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.For Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBH":"齐默巴奥米特控股"},"translate_title":"尽管第四季度表现出色，但2025年前景令人失望，Zimmer Biomet股价盘前暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1},"content_text":"Zimmer Biomet Holdings Inc. (ZBH) shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.\nFor Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee implants as well as sports medicine and trauma care products.\nHowever, the company's full-year 2025 adjusted profit guidance of $8.15 to $8.35 per share fell short of Wall Street's consensus estimate of $8.56. Zimmer Biomet expects a 1.5% to 2% negative impact on revenue due to a stronger U.S. dollar. Additionally, its recent acquisition of orthopedic surgical device maker Paragon 28 is expected to weigh on earnings by around 10 cents per share.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}